Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Current Taxes (2018 - 2025)

China SXT Pharmaceuticals (SXTC) has 8 years of Current Taxes data on record, last reported at $1.0 million in Q1 2025.

  • For Q1 2025, Current Taxes fell 2.0% year-over-year to $1.0 million; the TTM value through Mar 2025 reached $1.0 million, down 2.0%, while the annual FY2025 figure was $1.0 million, 2.0% down from the prior year.
  • Current Taxes reached $1.0 million in Q1 2025 per SXTC's latest filing, down from $1.1 million in the prior quarter.
  • Across five years, Current Taxes topped out at $1.2 million in Q1 2022 and bottomed at $1.0 million in Q1 2025.
  • Average Current Taxes over 5 years is $1.1 million, with a median of $1.1 million recorded in 2023.
  • Peak YoY movement for Current Taxes: increased 17.67% in 2021, then dropped 5.38% in 2023.
  • A 5-year view of Current Taxes shows it stood at $1.2 million in 2021, then increased by 0.56% to $1.2 million in 2022, then dropped by 5.38% to $1.1 million in 2023, then decreased by 4.74% to $1.1 million in 2024, then fell by 2.0% to $1.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Taxes were $1.0 million in Q1 2025, $1.1 million in Q1 2024, and $1.1 million in Q1 2023.